Posted by Michael Wonder on 27 Nov 2019
Revance submits biologics license application to the FDA for DAXI to treat glabellar (frown) lines
25 November 2019 - Revance Therapeutics today announced the Company has submitted a biologics license application to the U.S. FDA for daxibotulinumtoxinA for Injection (DAXI) in the treatment of moderate to severe glabellar (frown) lines.
The submission includes results from the SAKURA Phase 3 trials, which is the largest aesthetic neuromodulator clinical program ever conducted for the treatment of glabellar frown lines.
